CEL-SCI Co. (NYSE:CVM) Sees Large Decrease in Short Interest

Key Points

• CEL-SCI Co. (NYSE:CVM) experienced a significant 50.6% decrease in short interest in July, with total short interest falling from 1,540,000 shares to 760,700 shares.
• CEO Geert R. Kersten increased his position by 66.91%, purchasing 29,197 shares at $6.85 each, bringing his total ownership to 72,835 shares.
• Bank of America Corp DE significantly boosted its investment in CEL-SCI by 2,188.2% during the second quarter, acquiring 39,190 additional shares.

CEL-SCI Co. (NYSE:CVM - Get Free Report) saw a significant drop in short interest during the month of July. As of July 31st, there was short interest totaling 760,700 shares, adropof50.6% from the July 15th total of 1,540,000 shares. Based on an average daily volume of 815,300 shares, the short-interest ratio is presently 0.9 days. Approximately11.3% of the shares of the company are short sold. Approximately11.3% of the shares of the company are short sold. Based on an average daily volume of 815,300 shares, the short-interest ratio is presently 0.9 days.

Insider Buying and Selling

In related news, CEO Geert R. Kersten acquired 29,197 shares of the stock in a transaction dated Friday, July 25th. The shares were acquired at an average price of $6.85 per share, for a total transaction of $199,999.45. Following the completion of the purchase, the chief executive officer owned 72,835 shares in the company, valued at approximately $498,919.75. The trade was a 66.91% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 14.06% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

An institutional investor recently raised its position in CEL-SCI stock. MAI Capital Management increased its holdings in shares of CEL-SCI Co. (NYSE:CVM - Free Report) by 229.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 526,480 shares of the company's stock after acquiring an additional 366,880 shares during the quarter. MAI Capital Management owned approximately 0.63% of CEL-SCI worth $121,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 12.08% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen started coverage on CEL-SCI in a research report on Friday, May 16th. They set a "sell" rating for the company.

CEL-SCI Trading Up 4.5%

Shares of CVM stock traded up $0.4150 on Friday, hitting $9.5850. The company had a trading volume of 109,061 shares, compared to its average volume of 367,074. The firm has a market cap of $65.96 million, a P/E ratio of -19.97 and a beta of 0.52. The stock's 50-day moving average is $5.28 and its two-hundred day moving average is $6.83. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.09 and a current ratio of 1.07. CEL-SCI has a twelve month low of $1.98 and a twelve month high of $39.30.

CEL-SCI Company Profile

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.